MRK Trading Analysis - 10/23/2026 03:09 PM — TRU-SENTIMENT

News Headlines & Context

Recent general knowledge headlines and context for Merck & Co (MRK) that may be relevant to current trading conditions:

• Merck received FDA approval for an expanded indication of its key cancer immunotherapy Keytruda in combination therapy, supporting long-term pipeline optimism.
• Concerns over pending patent cliffs for Keytruda beyond 2028 continue to weigh on forward valuation sentiment among institutional holders.
• MRK declared a quarterly dividend with ex-dividend date of 2026-09-15 and current yield near 2.29%, providing income support amid volatility.
• No major near-term earnings catalyst appears scheduled before the next major options expiration of 2026-11-20 based on general knowledge.
• Headlines suggest balanced sector sentiment; this aligns with the embedded options data showing "Balanced" true sentiment and no directional spread recommendation.

The above news is contextual only and separated from the strict data-driven analysis below, which is based solely on embedded files.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS JSON (source: FinWin fundamentals local, as of 2026-10-23):

• Trailing P/E: 116.80; Trailing EPS: 1.27. No forward P/E, PEG, or price/book provided (all null).
• Market Cap: 356,802,414,640.00; Shares Outstanding: 2,467,172,000.00.
• Dividend Yield: 0.02 (2.29%); Dividend Rate: 3.40; Ex-Dividend: 2026-09-15.
• Beta: -0.02 (near market-neutral historically per data).
• 52-Week High: 156.92; 52-Week Low: 82.01.
• Institutional Percent: 55.21%; Average Volume: 9,228,000.00.
• Historical Volatility: 26.39%.
• Revenue growth, gross/operating/net margins, ROE, debt/equity, and free cash flow are null in data.
• Analyst consensus, target mean price, and recommendation key are null.

Fundamentally, the stock shows a high trailing P/E of 116.80 versus low EPS of 1.27, with no PEG to justify growth. The data lacks margin and revenue trend fields, so no fundamental strength/weakness can be confirmed beyond dividend and institutional ownership. This diverges from the technical picture, which shows moderate momentum (RSI 56.52) and price near 148.27, above 50-day SMA of 146.50.

Current Market Position

From DAILY HISTORY and MINUTE BARS (strictly embedded):

• Daily close on 2026-10-22: 148.27; intraday on 2026-10-23 14:40 last close: 144.62.
• Daily 2026-10-22 range: High 154.02, Low 144.07, Volume 15,631,637 (above 20d avg 5,904,980).
• Minute bars: 2026-10-22 open 151.05 fell to 147.35 by 15:55; 2026-10-23 14:30 open 145.02 dropped to low 143.41, closed 144.81, then 144.62 at 14:40.
• Intraday momentum: downward drift from 151.05 to 144.62 over two sessions; volume spike 5,353,488 at 14:30 10-23.

Technical Analysis

• SMA alignment: Price 148.27 > SMA5 147.23 > SMA50 146.50 > SMA20 145.47. No bearish cross; mild bullish stack but SMA20 below SMA50 shows prior consolidation.
• RSI 56.52: neutral-to-slightly bullish momentum, no overbought.
• MACD 0.81 > Signal 0.64, Hist +0.16: bullish bias, no divergence in data.
• Bollinger: Price 148.27 between middle 145.47 and upper 151.26; no squeeze (band width 11.57).
• 30d range: High 154.02, Low 138.80; price at 148.27 is ~63% up the range.

True Sentiment Analysis (Delta 40-60 Options)

From MRK_options_20261023_1509.json (methodology: Delta 40-60 only):

Call Dollar Volume: 1,145,530.00 (47.40%) Put Dollar Volume: 1,270,875.00 (52.60%) Total: 2,416,405.00

• Sentiment: Balanced (call_pct 47.4, put_pct 52.6).
• Contracts: Call 2040, Put 2359; Trades: Call 42, Put 35.
• Pure directional conviction: near-even; slight put dollar edge suggests mild defensive positioning.
• Filter ratio 5.9% (77 of 1314 analyzed); low sample of high-conviction options.

No divergence from technicals (both non-bearish); sentiment neither confirms nor invalidates upward SMA bias.

Key Price Levels (Observational Only)